Hong Hua

Carthamus tinctorius

Also known as: Safflower(English) False Saffron(English) American Saffron(English) Hong Hua(Chinese (Pinyin)) 红花(Chinese)

Kōka紅花 コウカ Honghwa紅花 홍화 Hồng hoa Hung Hua

Updated October 23, 2026 · Not yet clinically reviewed

Hong Hua

Safety at a glance

High risk

With warfarin, coumadin, anticoagulant: blood-invigorating → additive bleeding risk

Caution

Pregnancy: caution — blood-invigorator — ChP 2020: use with caution in pregnancy (孕妇慎用)

Caution

5 recorded drug interactions, 3 major or contraindicated

Note

Contraindications or side effects are listed

No rule in our tables for this herb: breastfeeding, incompatible pairs (十八反 / 十九畏), dose ceiling. This is not a safety clearance.
Not graded —

No toxicity grade is recorded. Most herbs in the catalogue carry none.

Traditional Chinese Medicine

Category
regulating blood
Temperature
Warm
Taste
Pungent
Channels
Heart,Liver,Lung

Functions

Invigorates the Blood, dispels Blood Stasis, opens the channels, unblocks menstruation and alleviates pain

Traditional uses

Hong Hua (红花) is the dried floret of Carthamus tinctorius L. (Asteraceae), Flos Carthami, safflower. It is acrid and warm, entering the Heart and Liver channels. It invigorates the Blood and dispels Blood stasis, opens the channels, unblocks menstruation, and alleviates pain.

It is one of the most-used Blood-invigorating herbs. It treats amenorrhoea and painful menstruation from stasis, retained lochia and postpartum abdominal pain, abdominal masses, and the fixed, stabbing pain of Blood stasis in the chest — where it is paired with Tao Ren in Xue Fu Zhu Yu Tang. It is a standard herb for traumatic injury with bruising, swelling and pain, and it is used for dark, poorly erupting measles rash.

Dose changes its character: a small amount is said to nourish and harmonise the Blood, a larger amount to break stasis. It is contraindicated in pregnancy, and used with caution in patients with bleeding tendencies or heavy menstrual flow. It should not be confused with Xi Hong Hua (saffron, Crocus sativus), a different and far more costly drug with a related but stronger Blood-cooling action.

Western herbalism

Properties: anti-inflammatory, antioxidant, carminative

Pharmacological effects

  • Cardiovascular: Injection 10 mg/kg i.v. increased coronary flow 60.4% in dogs (aqueous extract 58.5%; alcoholic extract 10-30 mg/kg no effect), though alcoholic extract improved epicardial electrogram in experimental infarction; decoction 0.2-2.0 g/kg i.v. lowered blood pressure in cats and dogs.
  • Anticoagulation: Alcoholic extract prolonged clotting, recalcification and thrombin times in dogs; extract and decoction inhibited ADP/collagen platelet aggregation; carthamin i.v. inhibited ADP aggregation in rabbits and rat thrombosis in vitro.
  • Effect on the uterus: Decoction stimulated isolated and in situ uteri of several species, more prominently when pregnant.
  • CNS: Safflor yellow A 550-1100 mg/kg i.p. gave longer-lasting analgesia than morphine in mice, was antiinflammatory in rats, potentiated barbital/chloral and reduced coramine convulsions.
  • Hypoxic endurance: In rats with acute hypoxic encephalopathy, alcoholic extract (0.5 g orally daily for 5 days plus 1 g i.p. pre-op) gave 83% survival vs 30% controls, with milder ischemic damage.

Source: Zhu YP. Chinese Materia Medica: Chemistry, Pharmacology and Applications. Harwood Academic, 1998, p. 472.

Formulas using this herb

62 of 62 formulas

Botanical

Carthamus tinctorius is an annual thistle-like herb in the daisy family (Asteraceae), growing 30-150 cm tall. Stems are stout, erect, and branched above. Leaves are alternate, sessile, oblong to lance-shaped, 3-10 cm long, with spiny teeth. Flower heads are 2-4 cm across, initially bearing bright yellow flowers that deepen to orange-red as they mature; these are the medicinal part (Hong Hua). Bracts are spiny. Seeds (white achenes) are a source of safflower oil. The red pigment (carthamin) gives the flowers their characteristic color.

Family
Asteraceae
Pharmaceutical name
Flos Carthami
Parts used
flower
Plant type
herb
Native region
Iran, Turkey
Conservation status
not_evaluated

Habitat

Cultivated in dry, warm climates throughout the world; native to southern Asia or the Middle East, widely grown for its seed oil, dye, and medicinal flowers.

Conservation notes

Carthamus tinctorius is a cultivated annual crop with long history of use for its seeds, oil, and dye. No wild populations are definitively known. Widely grown throughout China, India, and the Middle East. No conservation concerns.

Constituents

Hydroxysafflor yellow A

Quinochalcone C-glycoside · the Chinese Pharmacopoeia requires not less than 1.0% in the dried flower; it makes up roughly 80% of the safflor yellow used in Safflower Injection

The principal water-soluble active of the flower and the compound behind almost all of the modern cardiovascular and cerebrovascular evidence. It inhibits platelet aggregation, is anti-inflammatory, antioxidant and neuroprotective, and is the basis of the safflor yellow injection approved in China for angina pectoris and studied for acute ischaemic stroke. It is also the constituent that makes the antiplatelet interaction with warfarin pharmacologically expected rather than speculative.

Anhydrosafflor yellow B

Quinochalcone C-glycoside · the second major quinochalcone of the flower; not a Pharmacopoeia assay marker

Studied alongside hydroxysafflor yellow A using preparative HPLC and selective knock-out approaches in safflower herb pairs. Contributes to the yellow pigment fraction and to its cardiovascular activity, but is far less characterised than hydroxysafflor yellow A.

Carthamin

Quinochalcone (red pigment) · the red pigment of the petal; content rises as the flower matures and the petals turn from yellow to red

The water-insoluble red dye of safflower, historically the commercial reason the crop was grown. Its abundance relative to the yellow pigments tracks harvest timing, which is one reason petal colour is used as a crude quality indicator for the drug.

Kaempferol and its glycosides (including kaempferol-3-O-rutinoside)

Flavonol and flavonol glycosides · kaempferol is the second Chinese Pharmacopoeia assay marker for the drug, determined after acid hydrolysis of the methanol extract

The flavonol fraction of the flower and one of the two official quality markers. Kaempferol-3-O-rutinoside is also, with scutellarin, one of the two components identified by chemical fingerprinting combined with bioassay as a probable cause of the adverse reactions seen with Safflower Injection, so it is simultaneously a quality marker and a safety signal for the injectable route.

Scutellarin

Flavone glucuronide · a minor flavonoid of the flower, present in Safflower Injection

Identified together with kaempferol-3-O-rutinoside as a component likely responsible for the clinical adverse reactions of Safflower Injection when chemical fingerprinting was combined with bioassay. Relevant to the injectable form, not to oral decoction.

Luteolin

Flavone · present in the petal flavonoid fraction

One of the constituent flavones of the flower with anti-inflammatory and antioxidant activity in preclinical assays; not specific to safflower.

Serotonin (5-HT) derivatives and spermidine conjugates, including N-feruloylserotonin

Hydroxycinnamic acid amides of serotonin and spermidine · concentrated in the SEED, not the flower; a spermidine extraction yield of 2.894 mg/g has been reported

Antioxidant amide conjugates that are the signature of safflower SEED rather than of Flos Carthami. They are frequently quoted in reviews of the species and should not be attributed to the flower drug that this record describes.

Linoleic acid

Polyunsaturated fatty acid · the dominant fatty acid of safflower SEED oil; effectively absent from the flower drug

The constituent of safflower cooking oil. Human data on safflower oil and platelet aggregation do not transfer to Flos Carthami, and the regulatory conclusion that safflower oil as a food has no demonstrated abortifacient effect applies to the oil only, not to the flower.

Drug interactions

Warfarin

Major · Over-anticoagulation and bleeding; a documented INR rise to 5.31 with haematuria · Evidence level: Established

A 74-year-old man stable on warfarin 1.25 mg/day with a therapeutic INR developed haematuria after 14 days of taking safflower 20 g daily, with an INR of 5.31. On restarting the same warfarin dose without safflower his INR returned to 1.64-2.57. He had been taking twice the recommended maximum daily dose of 10 g. The mechanism appears to be pharmacodynamic rather than pharmacokinetic: in rats, combining Carthamus tinctorius with warfarin significantly prolonged prothrombin time and bleeding time WITHOUT changing the blood concentration of warfarin. Safflor yellow inhibits platelet adhesion and 5-HT release and raises free intracellular calcium. Safflower is one of the Chinese herbs assessed as having strong evidence of interaction with warfarin.

Clinical note: Treat as a real, dose-related interaction. Do not exceed 10 g daily, keep the dose constant, and check INR within one to two weeks of starting or stopping. Stop the herb and check INR urgently if haematuria, epistaxis or unexplained bruising appears.

Aspirin, clopidogrel, ticagrelor, dipyridamole and NSAIDs

Moderate · Additive antiplatelet effect and increased bleeding risk · Evidence level: Probable

Hydroxysafflor yellow A and the safflor yellow fraction inhibit platelet aggregation, inhibit platelet adhesion and suppress 5-HT release; this is the pharmacology behind the herb's approved cardiovascular use. Combining it with pharmaceutical antiplatelet agents is additive by design rather than by accident. In the acute cerebral infarction trial, safflower yellow injection given on top of standard antiplatelet therapy prolonged prothrombin time and lowered fibrinogen, which is direct evidence that the effects stack.

Clinical note: Usable with single antiplatelet therapy under monitoring, but be cautious on dual antiplatelet therapy, before surgery, or in a patient with peptic ulcer disease or any bleeding disorder. Stop at least one week before elective surgery.

Pregnancy: abortifacient, and additive with oxytocin, misoprostol and other uterotonics

Major · Miscarriage; documented placental damage and reduced neonatal survival in animals · Evidence level: Established

Hong Hua is a genuine abortifacient, not merely a precautionary contraindication. Safflower decoction excites uterine and intestinal smooth muscle, it has documented traditional use for fertility regulation and termination, and Carthamus tinctorius extract in mice produced toxic changes in placental structure and significantly reduced neonatal survival. Blood-invigorating herbs of this class stimulate uterine contraction and threaten an established pregnancy. The distinction that must be preserved: this applies to the FLOWER drug at medicinal doses, whereas safflower seed OIL used as a food has no clinical evidence of abortifacient effect.

Clinical note: Absolutely contraindicated in pregnancy at any stage. State this plainly to patients of childbearing potential and check pregnancy status before prescribing. Do not use it as an adjunct to pharmacological uterotonics outside a controlled obstetric setting.

Safflower Injection / safflor yellow injection (intravenous route)

Major · Anaphylactic shock, arrhythmia and severe cutaneous and respiratory allergic reactions · Evidence level: Established

The injectable preparation is a different risk article from the oral herb and must be kept separate. China's National Centre for ADR Monitoring collected 3,306 adverse reaction reports for Safflower Injection in 2012 alone, 154 of them (4.66%) classed as serious, predominantly skin and respiratory allergic reactions and arrhythmia. A pooled analysis of 14 published cases of anaphylactic shock found 57.14% occurred within ten minutes of administration and 78.57% within thirty minutes, the fastest at about two minutes; women accounted for 64.29% of cases and most patients were over 40. All 14 survived with oxygen, epinephrine and vasopressors. Chemical fingerprinting combined with bioassay identified scutellarin and kaempferol-3-O-rutinoside as probable causative components. Single overdose administration is an identified risk factor.

Clinical note: This hazard belongs to the injection, not to decocted Hong Hua. Never extrapolate the injection safety record onto oral use, and never extrapolate oral tolerance onto the injection. Where the injection is used, it must be given with resuscitation facilities and the patient observed for at least 30 minutes.

Anticoagulant and antiplatelet drugs in peptic ulcer disease or active bleeding

Moderate · Increased risk of gastrointestinal haemorrhage · Evidence level: Possible

Safflower is specifically cautioned in peptic ulcer disease and in bleeding disorders on the basis of its antiplatelet and anticoagulant pharmacology. There is no trial evidence quantifying gastrointestinal bleeding risk, but the combination of a mucosal lesion, an antiplatelet herb and an NSAID or anticoagulant is a recognised additive hazard.

Clinical note: Avoid in active peptic ulceration, recent gastrointestinal bleed, or thrombocytopenia. Take a bleeding history before prescribing.

Dosage

FormAmountFrequencyPopulationNotes
decoction3–10 gdailyadult
中国药典 2020年版 一部 【红花】【用法与用量】3~10g。 【注意】孕妇慎用。 — Chinese Pharmacopoeia 2020, Vol. I. Contraindicated in pregnancy; smaller doses nourish and harmonize Blood, larger doses invigorate and break Blood stasis.

Dui yao: classical pairings

Hong Hua + Tao Ren桃仁

The pair invigorates blood and breaks up stasis more powerfully than either herb alone, acting on both the upper and lower body.

Amenorrhea, dysmenorrhea and abdominal masses from blood stasis, and traumatic pain; the basis of Tao Hong Si Wu Tang (Yi Zong Jin Jian). Contraindicated in pregnancy.

Named pairing — Lü Jingshan, Shi Jinmo Dui Yao

Evidence

Study design on record, not certainty of outcome.

Randomized controlled trial
2
In vitro / animal
1
Other / unclassified
1

Effect and Safety of Hydroxysafflor Yellow A for Injection in Patients with Acute Ischemic Stroke of Blood Stasis Syndrome: A Phase II, Multicenter, Randomized, Double-Blind, Multiple-Dose, Active-Controlled Clinical Trial

Ming-zhe Hu, Zi-yi Zhou, Zhong-yu Zhou, Hui Lu, Min Gao, Long-min Liu, Hai-qing Song, An-ji Lin · Chinese Journal of Integrative Medicine · 2020 · RCT

Randomized controlled trial · Verified

A nine-centre Chinese phase II trial run from July 2013 to September 2015 in patients with moderate or severe acute ischaemic stroke of Blood Stasis syndrome. Patients were randomised to low-, medium- or high-dose hydroxysafflor yellow A injection (25, 50 or 70 mg/day intravenously) or to Dengzhan Xixin Injection 30 mL/day as active control, each for 14 consecutive days. The proportions achieving a modified Rankin Scale score of 1 or less at day 90 were significantly larger in the medium- and high-dose groups than in the control group, and the drug was safe and well tolerated at all doses. This is the strongest controlled evidence for the isolated main constituent, by the intravenous route, in a Chinese-syndrome-selected population.

doi:10.1007/s11655-020-3094-7

The Value of Safflower Yellow Injection for the Treatment of Acute Cerebral Infarction: A Randomized Controlled Trial

Le-Jun Li, Yu-Mei Li, Ben-Yu Qiao, Shan Jiang, Xin Li, Hong-Ming Du, Peng-Cheng Han, Jiong Shi · Evidence-Based Complementary and Alternative Medicine · 2015 · RCT

Randomized controlled trial · Not yet verified

A prospective single-blinded randomised controlled trial in 97 patients with acute ischaemic stroke (66 treatment, 31 control) given safflower yellow injection 80 mg daily or placebo for 14 days on top of standard antiplatelet and neuroprotective therapy. NIHSS scores fell significantly by days 7 and 14 in the treatment arm, red cell deformability and aggregation improved, prothrombin time lengthened, fibrinogen fell, and TNF-alpha, IL-1beta and IL-6 were significantly reduced. The authors acknowledged the small sample and incomplete blinding. A corrigendum was published in 2016 correcting the author list only; the paper itself has not been retracted. Note the haemostatic findings: this is direct trial evidence that the drug prolongs PT and lowers fibrinogen on top of antiplatelet therapy.

doi:10.1155/2015/478793

Combination of chemical fingerprinting with bioassay, a preferable approach for quality control of Safflower Injection

Wu W. Feng, Yi Zhang, Jin F. Tang, Cong E. Zhang, Qin Dong, Rui Y. Li, Xiao H. Xiao, Cheng Peng · Analytica Chimica Acta · 2018 · in vitro

In vitro / animal · Not yet verified

Chemical fingerprinting of Safflower Injection identified 33 compounds, and coupling the fingerprint to a bioassay pinned scutellarin and kaempferol-3-O-rutinoside as the components most likely responsible for the clinical adverse reactions reported with the preparation. Directly relevant to why the injectable route carries an allergy risk that oral Hong Hua does not.

doi:10.1016/j.aca.2017.11.069

A literature analysis on 14 cases of allergic shock caused by safflower injection

Z Sun, F Lian, J Zhang, J Sun, Y Guo, Y Zhang · African Journal of Traditional, Complementary and Alternative Medicines · 2013 · systematic review

Other / unclassified · Verified

A pooled literature analysis of 14 published Chinese case reports of anaphylactic shock following clinical use of safflower injection. Women made up 64.29% of cases and most patients were over 40. Onset was rapid: 57.14% within ten minutes of administration and 78.57% within thirty minutes, the fastest at about two minutes. Reactions occurred mainly during treatment of cardiovascular and cerebrovascular disease. All patients were managed with oxygen, epinephrine and vasopressors, and no patient died: six recovered within thirty minutes, five within two hours and three within a day. This is a case-series review, not a controlled study, so it establishes that the hazard is real and fast in onset but cannot give an incidence.

doi:10.4314/ajtcam.v10i6.31

Safety

Contraindications

Its use is prohibited in pregnant women, and cautious in patients with hemorrhagic tendency.

Source: Xi S, Gong Y. Essentials of Chinese Materia Medica and Medical Formulas. Academic Press/Elsevier, 2017, pp. 237–243.

⚠ Rule-based cautions

These entries come from the deterministic rule tables that gate Verscienta's formula tools: classical pair prohibitions, pregnancy and lactation contraindications, dose ceilings, and drugs outside the Chinese Pharmacopoeia. The botanical-genus entries are different: advisory notes are not part of the safety screen; the Aristolochia genus check is.

Pregnancy

Caution blood-invigorator — ChP 2020: use with caution in pregnancy (孕妇慎用)

Cultural and historical

Jin Gui Yao Lue · Eastern Han dynasty, Zhang Zhongjing, c. 200 CE

The earliest medicinal record of the herb, under the name Hong Lan Hua. In the chapter on miscellaneous diseases of women, Hong Lan Hua Jiu (Safflower Wine) is prescribed for abdominal pain in women, decocting the flower in wine so the wine carries its Blood-moving action into the channels. This is the origin of the herb's gynaecological Blood-stasis indication.

Kai Bao Ben Cao · Northern Song dynasty, 973-974 CE

The first printed Chinese materia medica, and the compilation in which safflower is entered as a formal drug rather than only as a formula ingredient.

Ben Cao Gang Mu · Ming dynasty, 1596

Li Shizhen records the dose-dependent distinction that still governs clinical use: a large dose breaks Blood stasis while a small dose nourishes and harmonises the Blood. This is why the same herb appears at 3 g in a tonifying formula and at 9-10 g in a stasis-breaking one.

References

  1. YT Chua, XL Ang, XM Zhong, KS Khoo. Interaction between warfarin and Chinese herbal medicines. Singapore Medical Journal. 2015 doi:10.11622/smedj.2015004
  2. Wei Zhuang, Shaoli Liu, Xusheng Zhao, Nan Sun, Tao He, Yali Wang, Beibei Jia, Xiaolan Lin. Interaction Between Chinese Medicine and Warfarin: Clinical and Research Update. Frontiers in Pharmacology. 2021 doi:10.3389/fphar.2021.751107
  3. Haotian Bai, Jing Yang, Rui Wang. Carthamus tinctorius L.: a comprehensive review of its ethnomedicine, phytochemistry, pharmacology, and clinical applications. Frontiers in Pharmacology. 2025 doi:10.3389/fphar.2025.1609299
  4. Jinous Asgarpanah, Nastaran Kazemivash. Phytochemistry, pharmacology and medicinal properties of Carthamus tinctorius L.. Chinese Journal of Integrative Medicine. 2013 doi:10.1007/s11655-013-1354-5
  5. Paula Mendonca Leite, Maria Auxiliadora Parreiras Martins, Maria das Gracas Carvalho, Rachel Oliveira Castilho. Mechanisms and interactions in concomitant use of herbs and warfarin therapy: An updated review. Biomedicine and Pharmacotherapy. 2021 doi:10.1016/j.biopha.2021.112103
© Verscienta Health — use subject to the API terms at https://verscienta.com/developers/api; educational reference, not medical advice